Q1 EPS Estimates for DENTSPLY SIRONA Reduced by Analyst

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Research analysts at Barrington Research decreased their Q1 2025 earnings estimates for shares of DENTSPLY SIRONA in a research note issued on Friday, November 8th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings per share of $0.38 for the quarter, down from their prior forecast of $0.51. Barrington Research has a “Outperform” rating and a $24.00 price target on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Barrington Research also issued estimates for DENTSPLY SIRONA’s Q2 2025 earnings at $0.49 EPS, Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at $0.57 EPS and FY2025 earnings at $1.95 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.02. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The company had revenue of $951.00 million during the quarter, compared to analyst estimates of $939.10 million. During the same quarter in the previous year, the company posted $0.49 EPS. DENTSPLY SIRONA’s revenue for the quarter was up .4% on a year-over-year basis.

A number of other research firms have also commented on XRAY. Leerink Partners lowered DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. Needham & Company LLC dropped their price target on DENTSPLY SIRONA from $34.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Stifel Nicolaus cut their price target on shares of DENTSPLY SIRONA from $30.00 to $28.00 and set a “hold” rating on the stock in a report on Thursday, July 18th. Leerink Partnrs lowered shares of DENTSPLY SIRONA from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, StockNews.com raised shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, DENTSPLY SIRONA presently has a consensus rating of “Hold” and a consensus price target of $29.50.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY opened at $17.65 on Monday. The company has a current ratio of 1.25, a quick ratio of 0.87 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average price of $24.52 and a 200-day moving average price of $25.74. The company has a market cap of $3.58 billion, a price-to-earnings ratio of -8.53, a price-to-earnings-growth ratio of 0.97 and a beta of 1.02. DENTSPLY SIRONA has a 12 month low of $17.21 and a 12 month high of $37.60.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors and hedge funds have recently made changes to their positions in the business. John G Ullman & Associates Inc. increased its holdings in shares of DENTSPLY SIRONA by 130.0% during the third quarter. John G Ullman & Associates Inc. now owns 193,006 shares of the medical instruments supplier’s stock valued at $5,223,000 after acquiring an additional 109,083 shares in the last quarter. LMR Partners LLP purchased a new stake in DENTSPLY SIRONA during the 3rd quarter valued at about $3,066,000. Quest Partners LLC grew its position in DENTSPLY SIRONA by 379.8% during the 3rd quarter. Quest Partners LLC now owns 109,832 shares of the medical instruments supplier’s stock valued at $2,972,000 after purchasing an additional 86,939 shares during the last quarter. AM Squared Ltd increased its stake in DENTSPLY SIRONA by 69.4% during the 3rd quarter. AM Squared Ltd now owns 6,100 shares of the medical instruments supplier’s stock valued at $165,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Natixis Advisors LLC raised its holdings in DENTSPLY SIRONA by 21.1% in the third quarter. Natixis Advisors LLC now owns 21,733 shares of the medical instruments supplier’s stock worth $588,000 after buying an additional 3,787 shares during the last quarter. Institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.